Physician profile
Pinal Doshi
NPI 1326062712
$3,086.78
in general payments reported to CMS, 2019-2025
14 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,157 · 2020: $94.02 · 2021: $211 · 2022: $78.21 · 2023: $144 · 2024: $245 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,909.95 | 2019-2022 | |
| Abbott Laboratories | $511.01 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $127.12 | 2019 | |
| Merck Sharp & Dohme LLC | $120.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $72.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.45 | 2019-2022 | |
| Novo Nordisk INC | $55.08 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $48.12 | 2019-2023 | Shingrix |
| Abbvie INC. | $44.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.55 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.37 | 2019 | |
| Roche Diabetes Care, INC. | $28.00 | 2019 | |
| Amarin Pharma, INC. | $22.57 | 2019 | |
| Lilly USA, LLC | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinal Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.